Top

Published in:

01-10-2020 | Breast Cancer | Original Article

Expression of SIRT1, SIRT3 and SIRT6 Genes for Predicting Survival in Triple-Negative and Hormone Receptor-Positive Subtypes of Breast Cancer

Authors: Bojana Uzelac, Ana Krivokuca, Mirjana Brankovic-Magic, Zvonko Magic, Snezana Susnjar, Zorka Milovanovic, Gordana Supic

Published in: Pathology & Oncology Research | Issue 4/2020

Abstract

Triple-negative breast cancer (TNBC) is characterized by aggressive phenotype and a poorer prognosis compared to the estrogen and progesterone receptor positive, Her2 negative (ER + PR + Her2-) breast cancer. Increasing evidence suggests that sirtuins, a family of histone deacetylases, could have an important role in aggressiveness of TNBC’s. The current study evaluated the potential clinical relevance of SIRT1, SIRT3 and SIRT6 gene expressions in two prognostically distinctive subtypes of breast cancer, the most aggressive TNBC and the least aggressive ER + PR + Her2- tumors. Total RNAs were isolated from 48 TNBC and 63 ER + PR + Her2- tumor samples. Relative gene expression was determined by SYBR Green RT-PCR and delta-delta Ct method, normalized to GAPDH. Mean gene expression of both SIRT1 and SIRT3 was significantly lower in the TNBC compared to ER + PR + Her2- tumors (p = 0.0001). Low SIRT1 and SIRT6 expressions associated with worse overall survival in ER + PR + Her2- patients (p = 0.039, p = 0.006, respectively), while TNBC patients with high SIRT1 tend to have a poor prognosis (p = 0.057). In contrast, high expression of SIRT3 in TNBC patients associated with higher histological grade (p = 0.027) and worse overall survival (p = 0.039). The Cox regression analysis revealed that low SIRT1 expression could be an independent prognostic marker of poor survival in ER + PR + Her2- breast cancers (HR = 11.765, 95% CI:1.234–100, p = 0.033). Observed differential expression of SIRT1, SIRT3 and SIRT6 genes in TNBC and ER + PR + Her2- subtypes, with opposite effects on patients’ survival, suggests context-dependent mechanisms underlying aggressiveness of breast cancer. Further investigations are necessary to evaluate sirtuins as potential biomarkers and therapeutic targets in breast cancer.

Available only for authorised users

Fallahpour S, Navaneelan T, De P, Borgo A (2017) Breast cancer survival by molecular subtype: a population-based analysis of cancer registry data. CMAJ Open 5(3):E734–E739CrossRef

Carafa V, Altucci L, Nebbioso A (2019) Dual tumor suppressor and tumor promoter action of Sirtuins in determining malignant phenotype. Front Pharmacol 10:38CrossRef

Jin M-S, Hyun CL, Park IA, Kim JY, Chung YR, Im S-A, Lee KH, Moon HG, Ryu HS (2016) SIRT1 induces tumor invasion by targeting epithelial mesenchymal transition-related pathway and is a prognostic marker in triple negative breast cancer. Tumor Biol 37(4):4743–4753CrossRef

Yeung F, Hoberg JE, Ramsey CS, Keller MD, Jones DR, Frye RA, Mayo MW (2004) Modulation of NF-kappaB-dependent transcription and cell survival by the SIRT1 deacetylase. EMBO J 23(12):2369–2380CrossRef

Yi YW, Kang HJ, Kim HJ, Kong Y, Brown ML, Bae I (2013) Targeting mutant p53 by a SIRT1 activator YK-3-237 inhibits the proliferation of triple-negative breast Cancer cells. Oncotarget 4(7):984–994CrossRef

Wang C, Yang W, Dong F, Guo Y, Tan J, Ruan S, Huang T (2017) The prognostic role of Sirt1 expression in solid malignancies: a meta-analysis. Oncotarget 8(39):66343–66351CrossRef

Bosch-Presegué L, Vaquero A (2011) The dual role of sirtuins in cancer. Genes Cancer 2(6):648–662CrossRef

Cao Y-W, Li W-Q, Wan G-X, Li Y-X, Du X-M, Li Y-C et al (2014) Correlation and prognostic value of SIRT1 and Notch1 signaling in breast cancer. J Exp Clin Cancer Res CR 33:97CrossRef

Chung YR, Kim H, Park SY, Park IA, Jang JJ, Choe J-Y, Jung YY, Im SA, Moon HG, Lee KH, Suh KJ, Kim TY, Noh DY, Han W, Ryu HS (2015) Distinctive role of SIRT1 expression on tumor invasion and metastasis in breast cancer by molecular subtype. Hum Pathol 46(7):1027–1035CrossRef

10.

Jeong SM, Haigis MC (2015) Sirtuins in Cancer: a balancing act between genome stability and metabolism. Mol Cells 38(9):750–758CrossRef

11.

Ansari A, Rahman MS, Saha SK, Saikot FK, Deep A, Kim K (2017) Function of the SIRT3 mitochondrial deacetylase in cellular physiology, cancer, and neurodegenerative disease. Aging Cell 16(1):4–16CrossRef

12.

He S, He C, Yuan H, Xiong S, Xiao Z, Chen L (2014) The SIRT 3 expression profile is associated with pathological and clinical outcomes in human breast cancer patients. Cell Physiol Biochem Int J Exp Cell Physiol Biochem Pharmacol 34(6):2061–2069CrossRef

13.

Huang N, Liu Z, Zhu J, Cui Z, Li Y, Yu Y, Sun F, Pan Q, Yang Q (2017) Sirtuin 6 plays an oncogenic role and induces cell autophagy in esophageal cancer cells. Tumor Biol 39(6):1010428317708532

14.

Khongkow M, Olmos Y, Gong C, Gomes AR, Monteiro LJ, Yagüe E, Cavaco TB, Khongkow P, Man EPS, Laohasinnarong S, Koo CY, Harada-Shoji N, Tsang JWH, Coombes RC, Schwer B, Khoo US, Lam EWF (2013) SIRT6 modulates paclitaxel and epirubicin resistance and survival in breast cancer. Carcinogenesis 34(7):1476–1486CrossRef

15.

Deng C-X (2009) SIRT1, is it a tumor promoter or tumor suppressor? Int J Biol Sci 5(2):147–152CrossRef

16.

Rifaï K, Judes G, Idrissou M, Daures M, Bignon Y-J, Penault-Llorca F, Bernard-Gallon D (2017) Dual SIRT1 expression patterns strongly suggests its bivalent role in human breast cancer. Oncotarget 8(67):110922–110930CrossRef

17.

Lee J-J, Lee HJ, Son B-H, Kim S-B, Ahn J-H, Ahn SD, Cho EY, Gong G (2016) Expression of FOXM1 and related proteins in breast cancer molecular subtypes. Int J Exp Pathol 97(2):170–177CrossRef

18.

Zhang S, Chen P, Huang Z, Hu X, Chen M, Hu S, Hu Y, Cai T (2015) Sirt7 promotes gastric cancer growth and inhibits apoptosis by epigenetically inhibiting miR-34a. Sci Rep 5:9787. https://doi.org/10.1038/srep09787CrossRefPubMedPubMedCentral

19.

Hajian-Tilaki K (2013) Receiver operating characteristic (ROC) curve analysis for medical diagnostic test evaluation. Casp J Intern Med 4(2):627–635

20.

Kim H, Kwon YM, Kim JS, Han J, Shim YM, Park J, Kim DH (2006) Elevated mRNA levels of DNA methyltransferase-1 as an independent prognostic factor in primary nonsmall cell lung cancer. Cancer 107(5):1042–1049CrossRef

21.

Chung SY, Jung YY, Park IA, Kim H, Chung YR, Kim JY, Park SY, Im SA, Lee KH, Moon HG, Noh DY, Han W, Lee C, Kim TY, Ryu HS (2016) Oncogenic role of SIRT1 associated with tumor invasion, lymph node metastasis, and poor disease-free survival in triple negative breast cancer. Clin Exp Metastasis 33(2):179–185CrossRef

22.

Desouki MM, Doubinskaia I, Gius D, Abdulkadir SA (2014) Decreased mitochondrial SIRT3 expression is a potential molecular biomarker associated with poor outcome in breast cancer. Hum Pathol 45(5):1071–1077CrossRef

23.

Wilking MJ, Ahmad N (2015) The role of SIRT1 in Cancer. Am J Pathol 185(1):26–28CrossRef

24.

Simic P, Williams EO, Bell EL, Gong JJ, Bonkowski M, Guarente L (2013) SIRT1 suppresses the epithelial-to-Mesenchymal transition in Cancer metastasis and organ fibrosis. Cell Rep 3(4):1175–1186. https://doi.org/10.1016/j.celrep.2013.03.019CrossRefPubMed

25.

Yuan J, Minter-Dykhouse K, Lou Z (2009) A c-Myc–SIRT1 feedback loop regulates cell growth and transformation. J Cell Biol 185(2):203–211CrossRef

26.

Elangovan S, Ramachandran S, Venkatesan N, Ananth S, Gnana-Prakasam JP, Martin PM, Browning DD, Schoenlein PV, Prasad PD, Ganapathy V, Thangaraju M (2011) SIRT1 is essential for oncogenic signaling by estrogen/estrogen receptor α in breast cancer. Cancer Res 71(21):6654–6664CrossRef

27.

Vaziri H, Dessain SK, Ng Eaton E, Imai SI, Frye RA, Pandita TK et al (2001) hSIR2(SIRT1) functions as an NAD-dependent p53 deacetylase. Cell 107(2):149–159CrossRef

28.

Wu M, Wei W, Xiao X, Guo J, Xie X, Li L, Kong Y, Lv N, Jia W, Zhang Y, Xie X (2012) Expression of SIRT1 is associated with lymph node metastasis and poor prognosis in both operable triple-negative and non-triple-negative breast cancer. Med Oncol 29(5):3240–3249CrossRef

29.

Santolla MF, Avino S, Pellegrino M, De Francesco EM, De Marco P, Lappano R et al (2015) SIRT1 is involved in oncogenic signaling mediated by GPER in breast cancer. Cell Death Dis 6:e1834CrossRef

30.

Torrens-Mas M, Pons DG, Sastre-Serra J, Oliver J, Roca P (2017) SIRT3 silencing sensitizes breast Cancer cells to cytotoxic treatments through an increment in ROS production. J Cell Biochem 118(2):397–406CrossRef

31.

Bae JS, Park S-H, Jamiyandorj U, Kim KM, Noh SJ, Kim JR, Park HJ, Kwon KS, Jung SH, Park HS, Park BH, Lee H, Moon WS, Sylvester KG, Jang KY (2016) CK2α/CSNK2A1 phosphorylates SIRT6 and is involved in the progression of breast carcinoma and predicts shorter survival of diagnosed patients. Am J Pathol 186(12):3297–3315CrossRef

32.

Igci M, Kalender ME, Borazan E, Bozgeyik I, Bayraktar R, Bozgeyik E, Camci C, Arslan A (2016) High-throughput screening of Sirtuin family of genes in breast cancer. Gene. 586(1):123–128CrossRef

33.

Wang D, Li C, Zhang X (2014) The promoter methylation status and mRNA expression levels of CTCF and SIRT6 in sporadic breast cancer. DNA Cell Biol 33(9):581–590CrossRef

34.

Ioris RM, Galié M, Ramadori G, Anderson JG, Charollais A, Konstantinidou G, Brenachot X, Aras E, Goga A, Ceglia N, Sebastián C, Martinvalet D, Mostoslavsky R, Baldi P, Coppari R (2017) SIRT6 suppresses Cancer stem-like capacity in tumors with PI3K activation independently of its Deacetylase activity. Cell Rep 18(8):1858–1868CrossRef

35.

Thirumurthi U, Shen J, Xia W, LaBaff AM, Wei Y, Li C-W, et al. (2014) MDM2-mediated degradation of SIRT6 phosphorylated by AKT1 promotes tumorigenesis and trastuzumab resistance in breast cancer. Sci signal. 7(336):ra71

Title: Expression of SIRT1, SIRT3 and SIRT6 Genes for Predicting Survival in Triple-Negative and Hormone Receptor-Positive Subtypes of Breast Cancer
Authors: Bojana Uzelac
Ana Krivokuca
Mirjana Brankovic-Magic
Zvonko Magic
Snezana Susnjar
Zorka Milovanovic
Gordana Supic
Publication date: 01-10-2020
Publisher: Springer Netherlands
Keywords: Breast Cancer
Breast Cancer
Published in: Pathology & Oncology Research / Issue 4/2020
Print ISSN: 1219-4956
Electronic ISSN: 1532-2807
DOI: https://doi.org/10.1007/s12253-020-00873-5

Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras

Prof. Fabrice Barlesi

Developed by: Springer Medicine

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 4/2020

Impact of the Proportion of Biopsy Positive Core in Predicting Biochemical Recurrence in Patients with Pathological Pt2 and Negative Resection Margin Status after Radical Prostatectomy

Clinicopathological Findings on 28 Cases with XP11.2 Renal Cell Carcinoma

PARP inhibitor Olaparib Enhances the Apoptotic Potentiality of Curcumin by Increasing the DNA Damage in Oral Cancer Cells through Inhibition of BER Cascade

Mid-Infrared Imaging Is Able to Characterize and Separate Cancer Cell Lines

Expression of the Serrated Markers Annexin A10 or Gremlin1 in Colonic Adenocarcinomas: Morphology and Prognostic Values

Elevated Microparticles, Thrombin-antithrombin and VEGF Levels in Colorectal Cancer Patients Undergoing Chemotherapy

Keynote webinar | Spotlight on antibody–drug conjugates in cancer